Drawing for SMARTOPICALS

USPTO serial 88568115

SMARTOPICALS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BROWN, TINA
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SMARTOPICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

B. Brett Heavner

B. Brett Heavner FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LL901 NEW YORK AVENUE N.W.WASHINGTON, DC 20001UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals for use in industry, science or photographyACTIVE—
003Non-medicated skin and hair care preparations; cosmetic preparations, including, preparations for the reconditioning of hair and skin after medicinal treatments; non-medicated soaps; non-medicated shampoos; non-medicated plasters and patches, namely, skin masks, Talcum powders, skin creams, body creams, skin lotions, body lotions, skin moisturizing gels and lip balm for the treatment of dermatological disorders, cancer and skin infectionsACTIVE—
005Pharmaceutical preparations for the treatment of cancer and dermatological, hematological, renal and endocrine disorders; solutions for medicated facial and body powders, namely, solutions for dermatological use for use in medicated facial and body powders, medicated facial and body talcum powders for the treatment of dermatological disorders such as psoriasis, actinic keratosis and atopic dermatitis, medicated facial and body creams for the treatment of dermatological disorders such as psoriasis, actinic keratosis and atopic dermatitis, medicated facial and body lotions for the treatment of dermatological disorders such as psoriasis, actinic keratosis and atopic dermatitis, medicated facial and body gels for the treatment of dermatological disorders such as psoriasis, actinic keratosis and atopic dermatitis, medicated plaster and patches, namely, medicated skin masks and medicated skin care preparations, for use in the treatment of dermatological disorders such as psoriasis, actinic keratosis and atopic dermatitis, namely, medicated facial and body creams, medicated facial and body lotions, medicated facial and body gels, and medicated plaster and patches, namely, medicated skin masks; medicated solutions for injection and medicated lip balm for the treatment of dermatological disorders, cancer and skin infections; medicated soaps; medicated shampoos; medical dressings, including wound dressings; dressings for the treatment of dermatological disorders, cancer and skin infectionsACTIVE—
009Applications, namely, downloadable mobile applications for monitoring and reporting physical and psychological incidents, including disease conditions; computer software, namely, downloadable automated computer software for controlling the efficacy and efficiency of health services for use by hospitals and other health service providers; providing online downloadable software applications containing information on the use of pharmaceutical products and for calculating use of medicineACTIVE—
010Medical apparatus and instruments, namely, medical devices for applying pharmaceutical preparations and for introducing pharmaceutical preparations into the human body in the nature of syringes for injection, needles for medical use, medical needles and introducers; medical syringes; injection needles, medical needles; medical and non-medical devices for the diagnosis or treatment of cancer and dermatological, hematological, renal and endocrine disorders, namely, medical apparatus for detecting cancer, medical device for detecting cancer, nuclear medicine diagnostic imaging apparatus; medical apparatus and units for dosage, measuring and monitoring, namely, medical needles and introducers; medical devices, namely, devices for measuring body surface area affected by disease; medical apparatus and instruments, for the treatment of cancer and dermatological, hematological, renal and endocrine disorders, namely, biofeedback sensors; micro needles for medical or medical diagnostic use; containers specially for medical wasteACTIVE—
016Printed matters, namely, books, booklets, brochures, papers, magazines, news releases, annual reports, newspapers and newsletters, leaflets, and instructional and teaching materials in the field of skin diseases and treatment of skinACTIVE—
035Data processing servicesACTIVE—
038Electronic transmission of information through mobile applications and websites; providing online forums for information and communication about skin diseases and treatment of skin; electronic data transmissionACTIVE—
041Production of training videos and audio and visual presentations in the field of skin diseases and treatment of skin; providing educational medical conferences and seminars in the field of skin diseases and treatment of skin; providing in-person educational forums in the field of skin diseases and treatment of skinACTIVE—
042pharmaceutical research services; medical research services in the field of cancer and dermatological, hematological, renal and endocrine disordersACTIVE—
044Providing medical information, consultancy and advisory services; medical and pharmaceutical consultation; pharmaceutical advice; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical counseling; medical services, including, medical care in the field of cancer and dermatological, hematological, renal and endocrine disorders; Medical services, namely, planning of medical treatment programs for the treatment of cancer and dermatological, hematological, renal and endocrine disorders; providing medical information and advice in the fields of cancer and dermatological, hematological, renal and endocrine disorders; providing a website featuring medical information; hygienic and beauty careACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 3, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 3, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 1, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 6, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 6, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 17, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 1, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 1, 2021ALIEASSIGNED TO LIE—
Feb 26, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 24, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 23, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 23, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 8, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 8, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 8, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 6, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Dec 8, 2020PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Nov 20, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 20, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Nov 20, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 20, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 20, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
May 21, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 21, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 21, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 7, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 6, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 6, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 9, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 5, 2019DOCKASSIGNED TO EXAMINER—
Aug 23, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 9, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance